Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

James Larkin(Royal Marsden Hospital), Vanna Chiarion‐Sileni, René González(University of Colorado Denver), Jean‐Jacques Grob(Aix-Marseille Université), C. Lance Cowey(The University of Sydney), Christopher D. Lao(University of Michigan), Dirk Schadendorf, Reinhard Dummer(University of Zurich), Michael Smylie, Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Pier Francesco Ferrucci(European Institute of Oncology), Andrew Hill(The University of Sydney), John Wagstaff(Singleton Hospital), Matteo S. Carlino(Melanoma Institute Australia), John B.A.G. Haanen(The Netherlands Cancer Institute), Michele Maio(University of Siena), Iván Márquez‐Rodas(Hospital General Universitario Gregorio Marañón), Grant A. McArthur(Peter MacCallum Cancer Centre), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Georgina V. Long(Mater Hospital), Margaret K. Callahan(Memorial Sloan Kettering Cancer Center), Michael A. Postow(Cornell University), Kenneth F. Grossmann(University of Utah), Mario Sznol(Yale New Haven Hospital), Brigitte Dréno(Hotel Dieu Hospital), Lars Bastholt(Odense University Hospital), Arvin Yang(Bristol-Myers Squibb (United States)), Linda M. Rollin(Bristol-Myers Squibb (United States)), Christine E. Horak, F. Stephen Hodi(Dana-Farber Cancer Institute), Jedd D. Wolchok(Cornell University)
New England Journal of Medicine
May 31, 2015
Cited by 8,120Open Access
Full Text

Abstract

BACKGROUND: Nivolumab (a programmed death 1 [PD-1] checkpoint inhibitor) and ipilimumab (a cytotoxic T-lymphocyte-associated antigen 4 [CTLA-4] checkpoint inhibitor) have been shown to have complementary activity in metastatic melanoma. In this randomized, double-blind, phase 3 study, nivolumab alone or nivolumab plus ipilimumab was compared with ipilimumab alone in patients with metastatic melanoma. METHODS: We assigned, in a 1:1:1 ratio, 945 previously untreated patients with unresectable stage III or IV melanoma to nivolumab alone, nivolumab plus ipilimumab, or ipilimumab alone. Progression-free survival and overall survival were coprimary end points. Results regarding progression-free survival are presented here. RESULTS: The median progression-free survival was 11.5 months (95% confidence interval [CI], 8.9 to 16.7) with nivolumab plus ipilimumab, as compared with 2.9 months (95% CI, 2.8 to 3.4) with ipilimumab (hazard ratio for death or disease progression, 0.42; 99.5% CI, 0.31 to 0.57; P<0.001), and 6.9 months (95% CI, 4.3 to 9.5) with nivolumab (hazard ratio for the comparison with ipilimumab, 0.57; 99.5% CI, 0.43 to 0.76; P<0.001). In patients with tumors positive for the PD-1 ligand (PD-L1), the median progression-free survival was 14.0 months in the nivolumab-plus-ipilimumab group and in the nivolumab group, but in patients with PD-L1-negative tumors, progression-free survival was longer with the combination therapy than with nivolumab alone (11.2 months [95% CI, 8.0 to not reached] vs. 5.3 months [95% CI, 2.8 to 7.1]). Treatment-related adverse events of grade 3 or 4 occurred in 16.3% of the patients in the nivolumab group, 55.0% of those in the nivolumab-plus-ipilimumab group, and 27.3% of those in the ipilimumab group. CONCLUSIONS: Among previously untreated patients with metastatic melanoma, nivolumab alone or combined with ipilimumab resulted in significantly longer progression-free survival than ipilimumab alone. In patients with PD-L1-negative tumors, the combination of PD-1 and CTLA-4 blockade was more effective than either agent alone. (Funded by Bristol-Myers Squibb; CheckMate 067 ClinicalTrials.gov number, NCT01844505.).


Related Papers

No related papers found

Powered by citation graph analysis